It has been shown by several groups of workers that in multiple sclerosis there are changes in the relative proportions of saturated and unsaturated fatty acids in the brain lipids (Baker, Thompson, and Zilkha, 1963; Gerstl, Tavaststjerna, Hayman, Eng, and Smith, 1965; Cumings, Shortman, and Skrbic, 1965; Arnetoli, Pazzagli, and Amaducci, 1969) , and also that there is a lowering of the level of linoleate in the serum (Thompson, 1966) . More recently, Gul, Smith, Thompson, Payling Wright, and Zilkha (1970) have found that the relative level of linoleate, expressed as a percentage of the five main fatty acids, is also reduced both in the platelets and in the red blood cells of patients with multiple sclerosis. It is relevant also to note that Clausen and M0ller (1967) have reported that rats bred and raised on a diet deficient in polyunsaturated fatty acid show an increased susceptibility to the development of allergic encephalomyelitis after the injection of a brain antigen.
In view, therefore, of this growing evidence in multiple sclerosis of an apparently widespread abnormality in the handling of certain fatty acids by the body, and since the view has been put forward that the high prevalence of multiple sclerosis in certain parts of the world may be related to a dietary deficiency of unsaturated fatty acids (Swank, 1950; Sinclair, 1956; Allison, 1963) , it seemed important to determine whether any difference could be revealed between healthy subjects and patients with multiple sclerosis in their ability to incorporate orally administered linoleate into the various types of plasma lipid.
It is well known that the feeding of diets with a high content of linoleate causes an increase of linoleate in the serum lipid fractions together with a decrease of oleate and sometimes of palmitate, palmitoleate. and stearate as well. In comparatively few cases have these changes been studied over a short time interval (Irwin and Wiese, 1961; Gunning, Michaels, Neumann, Splitter, and Kinsell, 1963; Nichaman, Sweeley, and Olson, 1967) , although indications exist that an increase of linoleate in the $-lipoproteins can be observed within hours after a single dose of corn oil (Farquhar and Ahrens, 1963) .
In a series of healthy control subjects and of patients with multiple sclerosis we have therefore measured the fatty acid patterns in serum, drawn after an overnight fast, both before and during a five day period when the normal diet was supplemented with linoleate, and during the two days after the cessation of these supplements. We have also studied the relative proportions of fatty acids in the separated triglyceride, cholesteryl ester, and phospholipid fractions of the serum samples. EXPERIMENTAL DESIGN OF EXPERIMENTS Blood samples were taken from the antecubital vein after an overnight fast on three days while the subject was on his or her normal diet, during the week before the start of the linoleate supplements. 25
The supplements were then added to the normal diet, and were continued for a five day period; blood samples were taken, each after an overnight fast, throughout this period, and a further two samples were taken on the two consecutive days after cessation of the linoleate supplements.
Two doses of the linoleate supplements were taken each day, moming and evening. Each dose consisted of 50 ml. of a sunflower seed oil emulsion containing 14-3 g linoleic acid, which was prepared for use in a controlled therapeutic trial which is being undertaken by one of us (K.J.Z.) together with Dr. H. Millar and Dr. M. Langman. The emulsion was made up as follows: 50 ml. sunflower seed oil 0-025 g Orange G dye 1-4 g methyl cellulose 20 2 ml. benzoic acid solution 0-18 g citric acid (BPC preparation) 0-02 g saccharin sodium 0 4 ml. orange flavour Water to 100 ml.
CONTROLS AND PATIENTS Fourteen members of the staff of The Middlesex Hospital Medical School acted as healthy controls for the experiment; their ages ranged from 19 to 59 years (mean = 36-3 years), and there were eight males and six females.
The 14 patients with multiple sclerosis consisted of seven males and seven females, whose ages ranged from 20 to 53 years (mean = 36-6 years), and were hospitalized throughout the 10 day experimental period, 13 of them in the National Hospital, Queen Square, London, and one in King's College Hospital, London. All the patients except one were fully ambulant, and were on a normal diet. The one bedridden patient with severe paraplegia and ataxia sat in a chair for one hour each day. He also took a normal hospital diet. Two of the patients were receiving ACTH at the time of the investigation, and one was on imipramine. The disease was in an active stage in all patients, and nine of them showed recent deterioration during the previous month.
MATERIALS Methanol was B.D.H. Analar grade. Other solvents were May and Baker reagent grade. Hexane, chloroform, benzene, and methanol were redistilled before use. One per cent (w/w) ethanol was added to the chloroform after distillation. Nitrogen was oxygen-free. Silicic acid was washed and activated as described by Rouser, O'Brien, and Heller (1961) .
EXTRACTION OF LIPIDS Lipids were extracted by the method of Folch, Lees, and Sloane Stanley (1957) . For the analysis of total fatty acids 0-5 ml. serum samples were taken, and for the fractionation experiments between 15 and 2-5 ml. For the analysis of total fatty acids an internal standard (C 21:0 methyl ester) was added to the serum sample before extraction to permit calculation of actual amounts of fatty acid present in mg/ml. FRACTIONATION OF LIPIDS For the fractionation experiments the total lipid extract, after being taken to dryness, was loaded onto a silicic acid column (1 cm diameter, 2-5 g) and fractionated, as described by Blomstrand, Gurtler, and Werner (1965) , to obtain cholesteryl esters, triglycerides, free fatty acids, and phospholipids. The free fatty acids were present in quantities too small for accurate measurement, and were discarded. SAPONIFICATION After removal of solvent under nitrogen the total lipid extract (for total fatty acids) or the column fractions (for fatty acids of lipid classes) were incubated with 2 ml. ethanolic KOH (6 ml. 33 % aqueous KOH and 94 ml. ethanol containing 4 mg hydroquinone) for 1 hr at 800; 2 ml. water were then added and the incubation continued at 80°for a further 10 min. After cooling, 1 drop of thymol blue was added, and the solution extracted twice with 3 ml. hexane. These hexane extracts were discarded, the alkaline lower layer acidified with IN HCI, and fatty acids extracted into 3 ml. hexane. The fatty acid extract was then taken to dryness under nitrogen, dissolved in 0-2 ml. hexane, and methylated using diazomethane.
GAS CHROMATOGRAPHY The methyl esters were run on 20% diethylene glycol succinate columns using a PerkinElmer F1 1 gas chromatograph. Table 1 summarizes the results of the measurements of the levels of oleate (18:1) and linoleate (18:2), expressed as percentages of the total fatty acids, in the unfractionated fasting serum samples obtained before, during, and after administration of the linoleate supplements. Values for the other fatty acids present in the serum lipids are not presented, as, with the exception of palmitate, the linoleate feeding produced no significant changes in their levels, while for palmitate (as well as for the other fatty acids measured) at no time was there a significant difference between the controls and the patients.
RESULTS
In the case of both the healthy controls and the multiple sclerosis patients the percentages of oleate and linoleate remained remarkably constant in the fasting specimens drawn during the period while they were living on their various normal diets before the linoleate supplementation (see Fig.) ; the individual variations within each of the two groups were also small. The mean levels for the males and for the females throughout this period did not differ significantly; nor was there any correlation with the age of the subject.
In confirmation of our earlier work, the mean level of linoleate for the multiple sclerosis patients (297 Y%) was significantly lower (p < 0-01) than that of the control subjects (33 7 %) during the presupplementation period. It will be seen that this was accompanied by an inverse difference in the percentages of oleate, resulting in the ratio 18:2/18:1 being decreased from for the controls to 1-05 for the patients (p < 0-001).
In the controls the five day period of linoleate Fig.) 18:2 and 18:1 in the multiple sclerosis patients produced by the linoleate feeding were even greater for days 2 to 5 of the feeding period than those produced in the controls, so that by day 4 of the feeding period no statistically significant difference existed between the control and multiple sclerosis groups in the percentages of either 18:2 or 18:1 (Table 1) . On the other hand, in the post-feeding period the level of both 18:2 and 18:1 in the multiple sclerosis sera appeared to revert rather more quickly towards the pre-feeding levels than did the levels in the control sera, so that by the second day after the end of the feeding period a statistically significant difference had reappeared between the two groups of subjects. Fatty acid measurements were carried out on the separated triglyceride, cholesteryl ester, and phospholipid fractions of the serum samples from 10 controls and 10 patients. In each of these fractions obtained from the pre-supplementation serum samples-that is, from patients existing on their normal diets-the percentage of 18:2 was lower, and of 18:1 higher, in the multiple sclerosis patients than in the controls. The indications from this preliminary work are that there may be significant differences in the extent of the changes in fatty acid percentages in the different fractions in the two groups of subjects as a result of the supplementation. Further work is in progress to elucidate this possibility.
DISCUSSION
In addition to confirming our earlier findings of low levels of linoleate in the serum of patients with multiple sclerosis the observations described above show also that the percentage of oleate is increased in these patients, so that the 18:2/18:1 ratio is strikingly changed (about 30 %). We (Table 2) which, we presume, indicates that considerable quantities are being absorbed both in the controls and in the patients. On present evidence, therefore, we are unable to account for the low serum linoleate levels found in multiple sclerosis patients on their normal unsupplemented diets. Various possibilities could, however, be suggested: for example it is possible, in terms of the known pathways for the metabolism of triglycerides, cholesteryl esters, and phospholipids, that a different metabolic pathway or pathways may come into operation when the amount of available linoleate is increased dramatically, as in the supplements which we have used in this work, and that in multiple sclerosis these pathways may be functioning normally, whereas in the absence of these large amounts of available linoleate an alternative metabolic pathway is in operation, which is defective in multiple sclerosis, the defect revealing itself in the slight but consistent lowering in the percentage of 18:2 incorporated into the different lipids. Alternatively, it may be that these large supplements of linoleate are sufficient to correct an abnormally high rate of utilization or loss of linoleate in patients on their normal diet. It is our hope that further experimental work may throw some light on the mechanisms, and their control, concerned in the incorporation of linoleate into these lipid fractions in multiple sclerosis. Meanwhile, however, our findings would appear to suggest that, since linoleate feeding can cause significant elevations of the low linoleate levels found in multiple sclerosis, a therapeutic trial of linoleate supplementation, such as is at present being carried out, is justified.
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